Kenalog and Vitreous floaters - a phase IV clinical study of FDA data

Summary:

Vitreous floaters is reported as a side effect among people who take Kenalog (triamcinolone acetonide), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Avastin, and have Diabetic retinal oedema.

The phase IV clinical study analyzes which people have Vitreous floaters when taking Kenalog. It is created by eHealthMe based on reports of 10,533 people who have side effects when taking Kenalog from the FDA, and is updated regularly.

What is Kenalog?

Kenalog has active ingredients of triamcinolone acetonide. It is often used in pain. eHealthMe is studying from 10,692 Kenalog users. Check the latest studies of Kenalog.

What is Vitreous floaters?

Vitreous floaters (spots before the eyes) is found to be associated with 834 drugs and 838 conditions by eHealthMe. Check the latest studies of Vitreous floaters.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 18, 2026

10,533 people reported to have side effects when taking Kenalog.
Among them, 23 people (0.22%) have Vitreous floaters.

Among these 23 people:

How long have people been on Kenalog when they have Vitreous floaters? *

What is the gender of people who have Vitreous floaters when taking Kenalog? *

female: 75 %
male: 25 %

What is the age of people who have Vitreous floaters when taking Kenalog? *

What are other drugs people take besides Kenalog? *

What are other side effects people have besides Vitreous floaters? *

Headache (pain in head): 6 people, 26.09%
Cataract (clouding of the lens inside the eye): 6 people, 26.09%
Insomnia (sleeplessness): 6 people, 26.09%
Weight Increased: 5 people, 21.74%
Fatigue (feeling of tiredness): 5 people, 21.74%
Hypoaesthesia (reduced sense of touch or sensation): 5 people, 21.74%
Visual Impairment: 5 people, 21.74%
Visual Acuity Reduced (reduced clearness of vision): 5 people, 21.74%
Vision Blurred: 5 people, 21.74%
Nasopharyngitis (inflammation of the nasopharynx): 4 people, 17.39%

What are the existing conditions these people have? *

Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 4 people, 17.39%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 3 people, 13.04%
Primary Myelofibrosis (primary disorder of the bone marrow): 3 people, 13.04%
Headache (pain in head): 2 people, 8.70%
Sinusitis (inflammation of sinus): 2 people, 8.70%
Asthma: 2 people, 8.70%
Retinal Vessel Occlusion (a blockage in one of the small arteries): 2 people, 8.70%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 8.70%
Diabetic Eye Disease: 2 people, 8.70%
Macular Degeneration (painless eye condition that leads to the gradual loss of central vision): 2 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Kenalog and have Vitreous floaters?

- Check whether Vitreous floaters is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kenalog:

Kenalog (10,692 reports)

Browse all side effects of Kenalog:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Vitreous floaters:

Vitreous floaters (834 drugs)

Browse all the conditions that are associated with Vitreous floaters:

Vitreous floaters (838 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on triamcinolone acetonide (the active ingredients of Kenalog) and Kenalog (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.